Synthesis and γ-secretase activity of APP substrate-based hydroxyethylene dipeptide isosteres
The synthesis and γ-secretase activity of a number of hydroxyethylene isosteres is reported.
Section snippets
Acknowledgements
We thank Drs. Jules Shafer and Steve Gardell (Merck Research Laboratories, West Point) for their interest in this work and Dr. Ute Gerhard for NOE measurements.24
References (24)
- et al.
J. Med. Chem.
(1999) - et al.
Tetrahedron
(2001) - et al.
Tetrahedron Lett.
(1990) - et al.
Nature (London)
(1998) - et al.
Drugs Aging
(2000) - et al.
Science
(2001)et al.Exp. Opin. Ther. Pat.
(1999) - et al.
Trends Neurosci.
(2001) - Felsenstein, K.; Smith, D. W.; Poss, M. A.; Chaturvedula, P.; Sloan, C. P. US 5703129,...
- et al.
J. Med. Chem.
(2000)
J. Med. Chem.
J. Med. Chem.
Nature-Cell Biol.
Proc. Natl. Acad. Sci. U.S.A.
Cited by (29)
Applications of fluorine-containing amino acids for drug design
2020, European Journal of Medicinal ChemistryCitation Excerpt :Hydrolysis of the ester and removal of the Boc-protecting group afforded 414. The novel γ-secretase inhibitor nirogacestat (PF-3084014, 417, Fig. 47) was originally developed by Pfizer as a potential treatment for AD although it is currently in clinical trials for the treatment of fibroma based on its Notch-inhibiting activity [252,253]. The landscape of γ-secretase inhibitors and modulators has recently been reviewed [253] and many contain fluorine, either attached directly to an aromatic ring or present as a CF3 group.
Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): A γ-secretase inhibitor with Aβ lowering activity in a transgenic mouse model of Alzheimer's disease
2007, Bioorganic and Medicinal Chemistry LettersChapter 3 Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease
2007, Annual Reports in Medicinal ChemistryCitation Excerpt :Piperidine sulfone 48 resulted from modification of hits from a pharmacophore-based computational search [109]. To explore the SAR of catalytic site ligands such as 26, by more closely aligning inhibitor structure with substrate, a hydroxyethylene analog of the Aβ40 V–I cleavage site (49) was prepared, but found to be inactive (Aβ IC50>10,000 nM), indicating that further understanding of the interaction of peptide isosteres with γ-secretase is needed [110]. Synthetically accessible hydroxyethylureas have been used to explore the steric and stereochemical requirements of the active site [111–113].
Stereoselective synthesis of 5-[(1S)-N-Boc-amino-(2S)-(3-fluorophenyl) ethyl]-dihydrofuran-2-one
2004, Tetrahedron LettersHydroxytriamides as potent γ-secretase inhibitors
2004, Bioorganic and Medicinal Chemistry LettersProbing pockets S2-S4′ of the γ-secretase active site with (hydroxyethyl)urea peptidomimetics
2004, Bioorganic and Medicinal Chemistry Letters